Case-fatality rate of major bleeding events in patients on dual antiplatelet therapy after percutaneous coronary intervention: A systematic review and meta-analysis.

Tritschler, Tobias; Patel, Anuj; Kraaijpoel, Noémie; Bhatt, Deepak L; De Luca, Giuseppe; Di Santo, Pietro; Feres, Fausto; Costa, Ricardo A; Hibbert, Benjamin; Isshiki, Takaaki; Le Gal, Grégoire; Castellucci, Lana A (2022). Case-fatality rate of major bleeding events in patients on dual antiplatelet therapy after percutaneous coronary intervention: A systematic review and meta-analysis. Research and practice in thrombosis and haemostasis, 6(7), e12834. Wiley 10.1002/rth2.12834

[img]
Preview
Text
Research_and_Practice_in_Thrombosis_and_Haemostasis_-_2022_-_Tritschler_-_Case_fatality_rate_of_major_bleeding_events_in.pdf - Published Version
Available under License Creative Commons: Attribution-Noncommercial-No Derivative Works (CC-BY-NC-ND).

Download (3MB) | Preview

Background

Assessment of the case-fatality rate (CFR) of major bleeding on dual antiplatelet therapy (DAPT) may improve balancing risks and benefits of different durations of DAPT following percutaneous coronary intervention (PCI).

Objectives

To determine the CFR of major bleeding in patients on DAPT after PCI and to compare rates among different durations of DAPT.

Methods

Medline, Embase, and CENTRAL were searched from inception to August 2021 for randomized trials that reported fatal bleeding among patients who were randomized to ≥1 month of DAPT following PCI. Summary estimates for CFRs of major bleeding were calculated using the random-effects inverse-variance method. Statistical heterogeneity was evaluated using the I 2 statistic.

Results

Of 2777 citations obtained by the search, 15 (48%) of 31 potentially eligible studies were excluded because fatal bleeding was not reported, leaving 16 studies that were included in the analysis. Overall, there were 823 major bleeding events including 91 fatal events in 48,884 patients who were assigned to receive DAPT during study follow-up. The CFR of major bleeding was 10.8% (95% confidence interval [CI], 7.1-16.2; I 2 = 50%) in the entire study population, and 13.8% (95% CI, 6.5-27.1; I 2 = 28%), 11.2% (95% CI, 6.7-18.0; I 2 = 0%), and 5.8% (95% CI, 3.0-11.1; I 2 = 0%) in those on short-term (≤6 months; n = 16,553), standard-term (12 months; n = 19,453), and long-term DAPT (>12 months; n = 10,238), respectively.

Conclusion

Fatal bleeding is not reported in many studies evaluating DAPT after PCI. The CFR of major bleeding on DAPT is substantial and may be higher in the first 12 months of DAPT than during long-term DAPT.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Department of General Internal Medicine (DAIM) > Clinic of General Internal Medicine
04 Faculty of Medicine > Department of General Internal Medicine (DAIM) > Clinic of General Internal Medicine > Centre of Competence for General Internal Medicine

UniBE Contributor:

Tritschler, Tobias

Subjects:

600 Technology > 610 Medicine & health

ISSN:

2475-0379

Publisher:

Wiley

Language:

English

Submitter:

Pubmed Import

Date Deposited:

10 Nov 2022 14:09

Last Modified:

05 Dec 2022 16:27

Publisher DOI:

10.1002/rth2.12834

PubMed ID:

36349260

Uncontrolled Keywords:

bleeding case‐fatality rate drug‐eluting stent dual antiplatelet therapy meta‐analysis percutaneous coronary intervention

BORIS DOI:

10.48350/174635

URI:

https://boris.unibe.ch/id/eprint/174635

Actions (login required)

Edit item Edit item
Provide Feedback